METHOD FOR MAINTAINING INCREASED INTRACELLULAR p53 LEVEL, INDUCED BY PLATINUM-BASED ANTICANCER DRUG, AND APPLICATION THEREOF

a technology of intracellular p53 and platinum-based anticancer drugs, which is applied in the direction of drug compositions, instruments, genetic material ingredients, etc., can solve the problems of slowing tumor growth, hdm2 affecting the capability of p53 transcription factor, and the anticancer effect of cisplatin not showing a consistent pattern, so as to reduce side effects of drug administration, effectively inducing the death of cancer cells, and increasing the expression level of intracellular p53

Inactive Publication Date: 2018-06-07
ENHANCEDBIO INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0065]According to the method of the present invention, which is characterized by administering a platinum-based anticancer drug and an siRNA against ubiquitin ligase to p53 to a subject in need thereof, in combination or sequentially, it is possible to maintain the increased expression level of intracellular p53 for a long time even after treatment with a low dose of platinum-based anticancer drug, thereby effectively inducing the death of cancer cells and minimizing the side effects of drug administration upon administration of a platinum-based anticancer drug, so that it can be usefully used for the development of a preventive or therapeutic agent for cancer.

Problems solved by technology

Thus, HDM2 interferes with the capability of the p53 transcription factor, which is able to bind to p53 in the nucleus and thereby promote expression of the target gene.
Restoring p53 function in tumor cells by anti-HDM2 therapy will result in slowing tumor growth and instead stimulate apoptosis.
), and there is a limitation in that the anticancer effect of cisplatin does not show a consistent pattern because the expression dynamics of p53 against cisplatin treatment are different depending on the kind of cell.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • METHOD FOR MAINTAINING INCREASED INTRACELLULAR p53 LEVEL, INDUCED BY PLATINUM-BASED ANTICANCER DRUG, AND APPLICATION THEREOF
  • METHOD FOR MAINTAINING INCREASED INTRACELLULAR p53 LEVEL, INDUCED BY PLATINUM-BASED ANTICANCER DRUG, AND APPLICATION THEREOF
  • METHOD FOR MAINTAINING INCREASED INTRACELLULAR p53 LEVEL, INDUCED BY PLATINUM-BASED ANTICANCER DRUG, AND APPLICATION THEREOF

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0091]Effect of Cisplatin and HPV E6 / E7 siRNA on TP53 in Cervical Cancer Cells

example 1-1

[0092]Effect of HPV E6 / E7 siRNA co-administered with Cisplatin in Cervical Cancer Cells

[0093]Cervical cancer cell and HeLa cervical cancer cell lines (HeLa; ATCC CCL-2) infected with HPV type 18 virus and SiHa cervical cancer cell lines (SiHa; ATCC HTB-35) infected with HPV type 16 virus were plated on a 6-well plate with 5×104 or 1×105 cells and cultured in RPMI 1640 or DMEM medium for 24 hours at 37° C. and 5% carbon dioxide, respectively. siRNA intracellular transfection was performed with DharmaFect (Dharmacon, Lafayette, Colo., USA) according to manufacturer's instructions.

[0094]HeLa cervical carcinoma cells infected with HPV type 18 virus were transformed by pooling with each of siRNAs of 426 and 450 sequences, or respectively. The HPV type 16 virus-infected siHa cell line was transformed by pooling siRNAs of 366, 448 and 497 sequences, or respectively.

[0095]In the Western blot, whole-cell lysate was extracted with RIPA buffer (10 mM Tris (pH.4), 0.15 M NaCl, 5 mM EDTA, 1% Tri...

example 1-2

[0099]Cell Apoptotic Effects of Cisplatin and HPV E6 / E7 siRNA

[0100]To investigate the effect of cisplatin (CDDP) and HPV E6 / E7 siRNA on cell viability in cervical cancer cells, the following experiment was conducted.

[0101]Cervical cancer cells, Hela and CaSki cells were transformed with HPV E6 / E7 siRNA and cultured for 24 hours with 10 μM of cisplatin. WST analysis was performed to confirm cell viability.

[0102]Cell counts were determined by water soluble tetrazolium salts (WST) (EZ-Cytox kit; Daeil Lab Service, Seoul, Korea). EZ-Cytox solution (50 μl) added to each well of a 12-well plate and incubated for 2 to 3 hours. Live cells were measured (485 nm) using a GENios Pro microplate reader (Tecan Trading AG, Mannedorf, Switzerland) in a 96-well plate.

[0103]As a result, as shown in FIG. 1B, cell viability was decreased in the treated group compared to the group not treated with cisplatin

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
wavelengthsaaaaaaaaaa
wavelengthsaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a method for maintaining the increased intracellular p53 level, induced by a platinum-based anticancer drug, and an application thereof and, more specifically, to a method for maintaining the increased intracellular p53 level in cells by administering a platinum-based anticancer drug and siRNA to ubiquitin ligase for p53 to a subject in need thereof in combination and sequentially, and a composition for promoting cancer cell apoptosis using the same.According to the method of the present invention, the increased intracellular p53 expression level can be maintained for a long period of time in spite of the treatment with a low-concentration platinum-based anticancer drug, thereby effectively inducing the apoptosis of cancer cells and minimizing the drug side effect caused by the administration of the platinum-based anticancer drug, and thus the present invention can be favorably used in the prevention of cancer or the development of cancer medicines.

Description

[0001]This application claims priority from U.S. Patent Application No. 62 / 148,403, filed Apr. 16, 2015, which is incorporated herein by reference in its entirety.TECHNICAL FIELD[0002]The present invention relates to a method for maintaining an increased intracellular p53 level, induced by platinum-based anticancer drug, and application thereof, and more particularly, to a method for maintaining an increased level of p53 in cells by administering a platinum-based anticancer drug and an siRNA against ubiquitin ligase to p53 to a subject in need thereof, in combination or sequentially, and a composition for promoting the death of cancer cells using the same.BACKGROUND OF THE INVENTION[0003]The tumor suppressor protein p53 plays a pivotal role in maintaining genome integrity in cells by regulating the expression of various arrays of genes responsible for DNA repair, cell cycle and growth arrest, and apoptosis [references [May et al., Oncogene 18 (53) (1999) p. 7621-7636]; [Oren, Cell D...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K33/24C12N15/113A61K31/7088A61P35/00C12Q1/6886A61K33/243
CPCA61K33/24C12N15/1137A61K31/7088A61P35/00C12Q1/6886C12N2310/14C12N2320/31C12Q2600/136A61K31/282G01N33/5011G01N2333/4748C12Q2600/106C12Q2600/118C12Q2600/158C12N15/1131A61K31/555A61K33/243A61K48/00C12Q1/68G01N33/53G01N33/569
Inventor SHINKIM, YOUNG DEUGJUNG, HUN SOONKIM, DEUK AERAJASEKARAN, NIRMAL
Owner ENHANCEDBIO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap